Feb 17, 2017 at 15:29 | Source:
Biocon shares gained 2.6 percent to hit a record high of Rs 1,123 after the US health regulator USFDA has accepted pharma major Mylan's biologics licence application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim.
Feb 17, 2017 at 14:50 | Source: PTI
US health regulator USFDA hasaccepted pharma major Mylan's biologics licence application(BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim,Biocon and Mylan have said.
Feb 17, 2017 at 09:51 | Source: CNBC-TV18
Biocon Thursday announced the US Food and Drug Administration has accepted Mylans Biologics License Application (BLA) for biosimilar chemotherapy drug Pegfilgrastim for review. Sharing details on the development with CNBC-TV18 Biocon Chairperson and Managing Director Kiran Mazumdar Shaw said, "This is a very important acceptance."
Feb 11, 2017 at 10:16 | Source:
The company on Friday said it plans to spend about USD 80 million in next two years as it prepares to take the lead biosimilar molecule bevacizumab into clinical trial.
Feb 10, 2017 at 16:28 | Source: CNBC-TV18
Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio.
Feb 09, 2017 at 22:30 | Source:
Aurobindo Pharma forayed into biosimilars with acquisition of four cell culture derived biosimilar products from Switzerland-based TL Biopharmaceutical AG. As part of the deal. TL will supply all the developmental data for four molecules and Aurobindo will develop and market these products globally.
Feb 09, 2017 at 22:04 | Source: PTI
Drug firm Aurobindo Pharma hasforayed into the biosimilar development space by acquiringfour cell culture derived products from Switzerland-based TLBiopharmaceutical AG.
Jan 25, 2017 at 11:02 | Source: CNBC-TV18
Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
Jan 12, 2017 at 09:44 | Source:
Biocon shares touched a record high of Rs 1,049.50 on Thursday, up nearly 5 percent intraday after the US health regulator has accepted biosimilar application for its proposed cancer drug.
Jan 12, 2017 at 08:56 | Source: PTI
The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the two companies said in a statement.
Messages on Biosimilar »

Torrent Pharma  

torrent pharma going to launch two biosimilar soon

about 3 hrs 5 min 48 sec ago


Platinum Member



next big trigger will be first biosimilar approval by EMA ! Filed in July last year... 210 days 60 non workingdays , approval may come by April-May 2017!!!

10.06 AM Feb 22nd


Gold Member



Merck plans India bio-production plant A Merck bio-production plant would provide critical infrastructure to small biotech and biosimilar firms in India who want to develop a process for a new biosimilar

12.51 PM Feb 21st


New Member

0 Follower

Aurobindo Pharm  

what are the biosimilar advantages

10.32 AM Feb 21st


Platinum Member


Aurobindo Pharm  

The Indian biosimilar market is poised for big growth, augured by the launch of new products, growing acceptance of biosimilars and the entry of new players like Aurobindo Pharma. It is expected to increase from $186 million in 2016 to $1.1 billion in 2020, according to industry estimates. Indian

7.09 PM Feb 19th

Wire News

Platinum Member


News Now  

US health regulator USFDA has accepted pharma major Mylan's biologics licence application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim, Biocon and Mylan have said.

2.50 PM Feb 17th


Platinum Member



biocon well set in bio-similars field; has some very positive devlopments

8.43 PM Feb 16th


New Member


Aurobindo Pharm  

aurobindo is working on about a dozen bio-similars now. Huge growth expected in a year.

9.25 PM Feb 14th


New Member


Aurobindo Pharm  

auto has forayed into biosimilars, a booming industry. will rally very soon, even if not will come back to initial price of 705. great stock great results. it`s just going down because the pharma industry is down today.

10.40 AM Feb 10th


New Member


Aurobindo Pharm  

Dear Fii see the growth of the company not profit , in the pharma company how many approvals done and growth , as it has acquired of four cell culture derived biosimilar products from Switzerland-based TL Biopharmaceutical AG. The branded market size of these four biosimilars, three of them

11.00 PM Feb 9th

News across the web »
Jul 17, 2015 at 00:30 | Source: FirstPost
Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.